Intl Stem Cell granted key patent for liver disease program

International Stem Cell Corp., or ISCO, announced that the United States Patent and Trademark Office, or USPTO, has granted the Company a patent for a method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells. This patent is a key element of ISCO's metabolic liver disease program and allows the company to produce the necessary quantities of precursor cells in a more efficient and cost effective manner. The patent, 8,268,621, adds to the company's growing portfolio of proprietary technologies relating to the development of potential treatments for incurable diseases using human parthenogenetic Stem Cells, or hpSC.

View Comments (0)